Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: Results of a randomised trial

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 1, 2008, Pages 49-56

  Schneider, Markus P ^a   Delles, Christian ^a   Klingbeil, Arnfried U ^a   Ludwig, Malte ^b   Kolloch, Rainer E ^c   Krekler, Michael ^d   Stumpe, Klaus O ^b   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Department of Medicine   (Germany)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Aorta; Blood pressure; Blood vessels; Renin angiotensin system; Therapeutics

Indexed keywords

AMLODIPINE; ATENOLOL; HYDROCHLOROTHIAZIDE; IRBESARTAN;

ADULT; AGED; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MEASUREMENT; CAROTID ARTERY PULSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; ESSENTIAL HYPERTENSION; FEMALE; HEMODYNAMICS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PULSE PRESSURE; PULSE WAVE; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATENOLOL; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 42249099645     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2008.003     Document Type: Article

References (29)

1. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23.
2. Ting CT, Chen CH, Chang MS, Yin FC. Short- and long-term effects of antihypertensive drugs on arterial reflections, compliance, and impedance. Hypertension 1995;26:524-30.
3. Chen CH, Nevo E, Fetics B et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalised transfer function. Circulation 1997;95:1827-36.
4. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001;38:932-7.
5. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001;38:434-8.
6. Chirinos JA, Zambrano JP, Chakko S et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005;45 980-5.
7. Millasseau SC, Patel SJ, Redwood SR, Hitter JM, Chowienczyk PJ. Pressure wave reflection assessed from the peripheral pulse: Is a transfer function necessary? Hypertension 2003;41:1016-20.
8. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: Comparison with atenolol. JACC 2004;43:92-9.
9. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-25.
10. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002;39 735-8.
11. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006;24:2131-41.
12. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet 2004;364:1684-9.
13. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: A meta-analysis. CMAJ 2006;174 1737-42.
14. Chen CH, Ting CT, Nussbacher A et al. Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure. Hypertension 1996;27:168-75.
15. Kelly HP, Hayward CS, Ganis J, Daley J, Avolio A, O'Rourke M. Non-invasive registration of the arterial pressure pulse waveform using high-fidelity applanation tonometry. J Vasc Med Biol 1989;1 142-9.
16. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE. AT1-receptor blockade improves augmentation index: A double-blind, randomised, controlled study. J Hypertens 2002;20:2423-8.
17. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
18. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: Differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19 214-19.
19. Mahmud A, Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: Beyond blood pressure reduction. Am J Hypertens 2002;15:1092-95.
20. Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension 2001;37:1429-33.
21. Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE. Effect of AT1-receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123-8.
22. Schiffrin EL, Park JB, Intengan HO, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-9.
23. Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vascu Health Risk Manage 2007;3:125-37.
24. Schindler C, Brosnihan KB, Ferrario CM et al. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (HAS) in veins: A randomised double-blind crossover trial in healthy subjects. J Clin Pharmacol 2007;47:112-20.
25. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000;525:263-270.
26. Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 2002;103:493-9.
27. Luchner A, Burnett JC, Jr., Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study. JACC 1998; 32:1839-44.
28. McEniery CM, Schmitt M, Qasem A et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004;44:305-10.
29. Lund-Johansen P. Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension. Br J Clin Pharmacol 1976;3:445-51.